Phase 2 Randomized, Cross-over Trial of Fezolinetant for Treatment of Vasomotor Symptoms in Patients Taking Endocrine Therapy (VEnT)
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Fezolinetant (Primary)
- Indications Vasomotor symptoms
- Focus Therapeutic Use
- Acronyms VEnT
- 16 Oct 2024 Planned End Date changed from 1 Oct 2026 to 1 Dec 2026.
- 16 Oct 2024 Planned primary completion date changed from 1 Jul 2026 to 1 Sep 2026.
- 16 Oct 2024 Planned initiation date changed from 1 Oct 2024 to 1 Dec 2024.